Can a smart drug deliver a toxic payload to prostate cancer cells?

NCT ID NCT07746713

Not yet recruiting Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent directly to them. The main goals are to assess the drug's safety and find the most suitable dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-98768111, an antibody-drug conjugate that targets a protein called KLK2 found on prostate cancer cells
What this could lead to: If successful, this could lead to a new targeted treatment option for advanced prostate cancer that has spread and stopped responding to current therapies.
What could go wrong: This is an early-phase trial, so the drug may not be effective or may cause significant side effects. The results will only show safety and dosing, not whether it works as a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.